Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | ECE1 | P42892 | 6/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 6/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6362899 | 1.00 | P2RY14 (0.54) | P2RY14KMT2AECE1POLBMEN1 | |
| SCHEMBL6361384 | 0.86 | ITGB3 (0.48) | KMT2AMEN1 | |
| SCHEMBL6362766 | 0.86 | ITGB3 (0.48) | KMT2AMEN1 | |
| SCHEMBL6361820 | 0.82 | ITGB3 (0.41) | ECE1 | |
| SCHEMBL6356970 | 0.82 | P2RY14 (0.56) | P2RY14KMT2APOLBMEN1KDM4E | |
| SCHEMBL6362113 | 0.82 | ALDH1A1 (0.38) | KMT2APOLBMEN1KDM4EMAPT | |
| SCHEMBL6357946 | 0.82 | ALDH1A1 (0.38) | KMT2APOLBMEN1KDM4EMAPT | |
| SCHEMBL6361418 | 0.81 | TMPRSS15 (0.42) | KMT2APOLBMEN1 | |
| SCHEMBL6355462 | 0.80 | ALDH1A1 (0.43) | KMT2APOLBMEN1MAPT | |
| SCHEMBL6353468 | 0.80 | ALDH1A1 (0.43) | KMT2APOLBMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154062-A1 | Substituted chiral allosteric hemoglobin modifiers | ALLOS THERAPEUTICS, INC. | 2005-07-14 | — | — | US | disclosed |
| US-6894185-B2 | Substituted chiral allosteric hemoglobin modifiers | Allós Therapeutics, Inc. (US) | 2005-05-17 | — | — | US | disclosed |
| US-20030130523-A1 | Substituted chiral allosteric hemoglobin modifiers | ABRAHAM DONALD J (US) | 2003-07-10 | — | — | US | disclosed |
| US-6486342-B1 | Substituted chiral allosteric hemoglobin modifiers | VIRGINIA COMMONWEALTH UNIVERSITY | 2002-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130523-A1 | Substituted chiral allosteric hemoglobin modifiers | HBZ, HBB, HBG2 | P2RY14 1138/4885KMT2A 1425/4885ECE1 1817/4885 |
| US-20050154062-A1 | Substituted chiral allosteric hemoglobin modifiers | HBZ, HBB, HBG2 | P2RY14 1138/4885KMT2A 1425/4885ECE1 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.